• Ophthalmic Mutual Insurance Company (OMIC)

    Note: This form is intended as a sample form of the information that you as the surgeon should personally discuss with the patient. Please review and modify to fit your actual practice. Give the patient a copy and send this form to the hospital or surgery center as verification that you have obtained informed consent.

    INDICATIONS

    Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 years of age. There are two types of macular degeneration: dry and wet. In the “wet” form of AMD, abnormal blood vessels grow in the back of the eye. Sometimes these vessels leak blood or fluid that causes blurred or distorted vision. Without treatment, vision loss may be quick and severe.

    Refractory macular edema, or swelling around the macula, is edema that affects vision but does not respond adequately to the usual treatment methods. It can occur with retinal vein occlusion (RVO) and diabetes (a condition called diabetic macular edema or DME). Without effective treatment, vision loss could progress and become permanent.

    POSSIBLE BENEFITS

    Lucentis™ (ranibizumab) was approved for AMD and refractory macular edema in RVO and DME based upon research that shows that VEGF is one of the causes for the growth of the abnormal vessels and edema that cause these conditions. Some patients treated with Lucentis™ (ranibizumab) had less fluid and more normal-appearing maculas, and their vision improved. Lucentis™ (ranibizumab) is also used, therefore, to treat macular edema, or swelling of the macula in RVO and DME.

    POSSIBLE LIMITATIONS AND ADMINISTRATION

    The goal of treatment is to prevent further loss of vision. Although many patients have regained vision, the medication may not restore vision that has already been lost, and may not ultimately prevent further loss of vision caused by the disease. After the pupil is dilated and the eye is numbed with anesthesia, the medication is injected into the vitreous, or jelly-like substance in the back chamber of the eye. Lucentis™ (ranibizumab) is administered by an injection into your eye as needed at regular intervals (about every four weeks); your ophthalmologist will tell you how often you will receive the injection, and for how long.

    ALTERNATIVES

    You do not have to receive treatment for your condition, although without treatment, these diseases can lead to further vision loss and blindness, sometimes very quickly. Other forms of treatment are available. At present, there are three other FDA-approved treatments for neovascular age-related macular degeneration (AMD): photodynamic therapy with a drug called Visudyne™ (verteporfin) and injection into the eye of the drugs Macugen™ (pegaptanib) and Eylea™ (aflibercept). Although Visudyne™ (verteporfin) and Macugen™ (pegaptanib) have been proven to slow down the rate of visual loss, most people do not get back better vision. The results with Eylea™ (aflibercept) are similar to Lucentis™ (ranibizumab). Three drugs have been approved for RVO: Lucentis™ (ranibizumab), Eylea™ (aflibercept), and Ozurdex™ (dexamethasone). Some eye surgeons use an anti-VEGF drug called Avastin™ (bevacizumab) to treat AMD and refractory macular edema; this use of Avastin™ is off-label. Eye surgeons also use triamcinolone acetonide, a long-acting cortisone-like drug (Kenalog™, Triesence™, or Trivaris™) to treat eye conditions like yours. Your doctor will discuss with you the benefits and risks associated with these other choices of treatment.

    COMPLICATIONS FROM THE MEDICATION AND INJECTION

    Your condition may not get better or may become worse. Any or all of these complications may cause decreased vision and/or have a possibility of causing blindness. Additional procedures may be needed to treat these complications. During the follow-up visits or phone calls, you will be checked for possible side effects and the results will be discussed with you.

    COMPLICATIONS OF LUCENTIS ™ (RANIBIZUMAB)

    Possible complications and side effects of the procedure and administration of Lucentis™ (ranibizumab) include but are not limited to retinal detachment, cataract formation (clouding of the lens of the eye), glaucoma (increased pressure in the eye), hypotony (reduced pressure in the eye), damage to the retina or cornea (structures of the eye), and bleeding. There is also the possibility of an eye infection (endophthalmitis). You may receive eye drops with instructions on when to use them to reduce the possibility of this occurring. Any of these rare complications may lead to severe, permanent loss of vision.

    There is a potential risk of arterial thromboembolic events (ATEs), defined as nonfatal stroke, nonfatal heart attack, and arterial death, following intravitreal use of anti-VEGF drugs. The rate of ATEs was low during the clinical trials. Whenever a medication is used in a large number of patients, a small number of coincidental life-threatening problems may occur that have no relationship to the treatment. Patients with diabetes are already at increased risk for heart attacks and strokes, and the clinical trial conducted in order to approve this drug for diabetic macular edema showed that diabetic patients had slightly more deaths. There were not many deaths, and the cause was typical of patients with advanced diabetic complications. It is not clear, therefore, whether the drug or the diabetes caused the deaths.

    KNOWN RISKS OF INTRAVITREAL EYE INEJCTIONS

    Patients receiving an injection of Lucentis™ (ranibizumab) may experience less severe side effects related to the pre-injection preparation procedure (eyelid speculum, anesthetic drops, dilating drops, antibiotic drops, povidone-iodine drops and the injection of the anesthetic). These side effects may include eye pain, subconjunctival hemorrhage (bloodshot eye), vitreous floaters, irregularity or swelling of the cornea, inflammation of the eye, and visual disturbances.

    PATIENT RESPONSIBILITIES

    I will immediately contact my ophthalmologist if any of the following signs of infection or other complications develop: pain, blurry or decreased vision, sensitivity to light, redness of the eye (compared to immediately after the injection), or discharge from the eye. I have been instructed NOT to rub my eyes or swim for three days after each injection. I will keep all post-injection appointments or scheduled telephone calls so my doctor can check for complications.

    PATIENT CONSENT

    The above explanation has been read by/to me. The nature of my eye condition has been explained to me and the proposed treatment has been described. The risks, benefits, alternatives, and limitations of the treatment have been discussed with me. All my questions have been answered.

    I hereby authorize Dr. __________________ to administer the intravitreal injection of Lucentis™ (ranibizumab) in my _____ Right eye _____ Left eye at regular intervals as needed. This consent will be valid until I revoke it or my condition changes to the point that the risks and benefits of this medication for me are significantly different.

    Patient signature
    Date